Evidence map›Paper›PMID 15007110›Full record

Trial reportThe New England journal of medicine2004

Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

Christopher P Cannon, Eugene Braunwald, Carolyn H McCabe, Daniel J Rader, Jean L Rouleau, Rene Belder, Steven V Joyal, Karen A Hill, Marc A Pfeffer, Allan M Skene and 1 more

Erratum issued 10 registry-linked trialsOpen access · bronzeAbstract readClinical TrialComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Trial report in The New England journal of medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 10 registered trials, which are not on this map. Cited by 1,231 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,231citing papers in PubMed, 10 pooled it
422.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01200056 phase4completedstarted 2007, after this paper: background citation

A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound

Ran2007Enrolled40Registered outcomes2Posted comparisons0ConditionsCoronary Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Ultrasonography, InterventionalArmsAtorvastatin 10mg versus 40mg.
PMID 15519006PMID 15249516PMID 15755765PMID 12114036PMID 12390948PMID 12176951PMID 10687795PMID 11277825PMID 11300468PMID 11368702PMID 11468198PMID 11584167other papers from this trial
Open the trial in the graph
NCT02428374 phase4unknown statusstarted 2015, after this paper: background citation

Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)

Ran2015Enrolled300Registered outcomes30Posted comparisons0ConditionsMyocardial FibrosisArmsRosuvastatin plus clopidogrel, Rosuvastatin plus ticagrelor, Simvastatin plus clopidogrel, Simvastatin plus ticagrelor
PMID 19329822PMID 24447629PMID 20702973PMID 19942084PMID 20031900PMID 22569318PMID 19764857PMID 21742096PMID 15975672PMID 19329177PMID 18997196PMID 18823627other papers from this trial
Open the trial in the graph
NCT03696940 phase3unknown statusstarted 2018, after this paper: background citation

Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina

Ran2018Enrolled120Registered outcomes6Posted comparisons0ConditionsCardiovascular Risk Factor, DyslipidemiasArmsAtorvastatin 10mg, L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
PMID 27046161PMID 25537708PMID 24793440PMID 24793441PMID 24793443PMID 16034009PMID 26939026PMID 17039901PMID 23190071PMID 19604523PMID 25915661PMID 19618992other papers from this trial
Open the trial in the graph
NCT06782243 nacompletedstarted 2024, after this paper: background citation

Comparison of High and Moderate Intensity Statins in Achieving the Target LDL-C Level After Acute Coronary Syndrome: Randomized Controlled Trial

Ran2024Enrolled190Registered outcomes10Posted comparisons0ConditionsAcute Coronary SyndromeArmsHigh-Intensity Statins, Moderate-Intensity Statins
PMID 15755765PMID 23736519PMID 21067804other papers from this trial
Open the trial in the graph
NCT00552747 phase4completednot on this mapstarted 2007, after this paper: background citation

The Effect of Fenofibrate on Endothelial Function and HDL in Patients With Coronary Heart Disease and LDL-C at Goal

TypeinterventionalSponsorNational Heart Institute, MexicoRan2007 to 2011Enrolled76ConditionsCoronary Heart Disease, HyperlipidemiaArmsfenofibrate, placebo
NCT00673036 unknown statusnot on this mapstarted 2005, after this paper: background citation

French Registry of Acute Coronary Syndrome With or Without ST Elevation

TypeobservationalSponsorAssistance Publique - Hôpitaux de ParisRan2005 to 2019Enrolled3,750ConditionsAcute Myocardial InfarctionArmsBlood sample
NCT01131299 phase2completednot on this mapstarted 2010, after this paper: background citation

Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol

TypeinterventionalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran2010 to 2015Enrolled103ConditionsCardiovascular DiseaseArmsPlacebo, Alpha cyclodextrin
NCT05514938 phase2completednot on this mapstarted 2022, after this paper: background citation

Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population

TypeinterventionalSponsorUniversity of Texas Southwestern Medical CenterRan2022 to 2025Enrolled140ConditionsAcute Coronary Syndrome, Lipid Disorder, Coronary Artery DiseaseArmsPolypill, Usual Care (individual medications prescribed by primary cardiologist)
NCT06083961 phase4not yet recruitingnot on this mapstarted 2023, after this paper: background citation

The Effect of Early Administration of PCSK9 Inhibitor, Alirocumab to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile, a Single Center Study, Registry Based, Pragmatic, Prospective Trial

TypeinterventionalSponsorSun U. KwonRan2023 to 2026Enrolled200ConditionsStroke, Acute Ischemic, PCSK9 InhibitorArmsAlirocumab
NCT07290699 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

INtensive Cholesterol-Lowering With recatIcimab combiNation in Emergency PCI for Acute Myocardial Infarction: A Randomized Controlled Trial

TypeinterventionalSponsorSecond Affiliated Hospital of Nanchang UniversityRan2026 to 2028Enrolled2,442ConditionsSTEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)ArmsRecaticimab
3 · Its place in the literature

Who cites it

1,231 citing papers in PubMed, 10 syntheses or guidelines pooled it, 4,914 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Preoperative statin therapy for adults undergoing cardiac surgery.The Cochrane database of systematic reviews · 2024
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Observational
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1,171 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Christopher P CannonThrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. cpcannon@partners.org
Eugene Braunwald
Carolyn H McCabe
Daniel J Rader
Jean L Rouleau
Rene Belder
Steven V Joyal
Karen A Hill
Marc A Pfeffer
Allan M Skene
Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Brigham and Women's Hospital · USHarvard University · USNottingham Biomedical Research Centre · GBPhiladelphia University · USUniversité de Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear.

methodsWe enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). The primary end point was a composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke. The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. Follow-up lasted 18 to 36 months (mean, 24).

resultsThe median LDL cholesterol level achieved during treatment was 95 mg per deciliter (2.46 mmol per liter) in the standard-dose pravastatin group and 62 mg per deciliter (1.60 mmol per liter) in the high-dose atorvastatin group (P<0.001). Kaplan-Meier estimates of the rates of the primary end point at two years were 26.3 percent in the pravastatin group and 22.4 percent in the atorvastatin group, reflecting a 16 percent reduction in the hazard ratio in favor of atorvastatin (P=0.005; 95 percent confidence interval, 5 to 26 percent). The study did not meet the prespecified criterion for equivalence but did identify the superiority of the more intensive regimen.

conclusionsAmong patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen. These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.

Indexed as

Angina, UnstableAnticholesteremic AgentsAtorvastatinCardiovascular DiseasesCholesterol, HDLCholesterol, LDLFemaleHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMyocardial InfarctionPravastatinProportional Hazards ModelsPyrrolesAnticholesteremic AgentsAtorvastatinCholesterol, HDLCholesterol, LDLHeptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsPravastatinPyrroles

Identifiers

PMID15007110
OpenAlexW2159449551

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

and 4 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.